Corline Biomedical AB

Research Corline Biomedical AB (CLBIO) on Bullrun: market cap SEK 459.94M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCLBIO
• ExchangeST
• CountrySweden
• SectorHealthcare
• IndustryBiotechnology
• CurrencySEK
• Market capSEK 459.94M
• Financial periodQ4 2025
• RevenueSEK 2.10M
• Net income-SEK 5.03M
• Free cash flow-SEK 6.82M
• Gross margin67.9%

Valuation Snapshot

latest market cap is SEK 459.94M.

About Corline Biomedical AB

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting.

Frequently asked questions

What is Corline Biomedical AB's market cap?

Corline Biomedical AB's market capitalization is SEK 459.94M.

What does Corline Biomedical AB do?

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden.